FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4365148103> ?p ?o ?g. }

• W4365148103 endingPage "2245" @default.
• W4365148103 startingPage "2245" @default.
• W4365148103 abstract "Despite the wide development of 90Y-loaded microspheres, 188Re-labeled lipiodol is still being used for radioembolization of hepatocellular carcinoma (HCC). However, the use of this latter compound is limited by in vivo instability. This study sought to evaluate the safety, bio-distribution, and response to 188Re-SSS lipiodol, a new and more stable compound.Lip-Re-01 was an activity-escalation Phase 1 study involving HCC patients progressing after sorafenib. The primary endpoint was safety based on Common Terminology Criteria for Adverse Events (AEs) of Grade ≥3 within 2 months. Secondary endpoints included bio-distribution assessed by scintigraphy quantification from 1 to 72 h, tumor to non-tumor uptake ratio (T/NT), as well as blood, urine and feces collection over 72 h, dosimetry, and response evaluation (mRECIST).Overall, 14 heavily pre-treated HCC patients were treated using a whole liver approach. The mean injected activity was 1.5 ± 0.4 GBq for activity Level 1 (n = 6), 3.6 ± 0.3 GBq for Level 2 (n = 6), and 5.0 ± 0.4 GBq for Level 3 (n = 2). Safety was acceptable with only 1/6 of Level 1 and 1/6 of Level 2 patients experiencing limiting toxicity (one liver failure; one lung disease). The study was prematurely discontinued unrelated to clinical outcomes. Uptake occurred in the tumor, liver, and lungs, and only sometimes in the bladder. The T/NT ratio was high with a mean of 24.9 ± 23.4. Cumulative urinary elimination and fecal eliminations at 72 h were very low, 4.8 ± 3.2% and 0.7 ± 0.8%, respectively. Partial response occurred in 21% of patients (0% in the first activity level; 37.5% in the others).The high in vivo stability of 188Re-SSS lipiodol was confirmed, resulting in encouraging responses for a Phase 1 study. As the 3.6 GBq activity proved to be safe, it will be used in a future Phase 2 study." @default.
• W4365148103 created "2023-04-13" @default.
• W4365148103 creator A5017605873 @default.
• W4365148103 creator A5032410140 @default.
• W4365148103 creator A5036152679 @default.
• W4365148103 creator A5037048002 @default.
• W4365148103 creator A5062453235 @default.
• W4365148103 creator A5065381120 @default.
• W4365148103 creator A5069522018 @default.
• W4365148103 creator A5070418195 @default.
• W4365148103 creator A5081103160 @default.
• W4365148103 creator A5082155887 @default.
• W4365148103 creator A5088831248 @default.
• W4365148103 date "2023-04-11" @default.
• W4365148103 modified "2023-09-25" @default.
• W4365148103 title "188Re-SSS Lipiodol Radioembolization in HCC Patients: Results of a Phase 1 Trial (Lip-Re-01 Study)" @default.
• W4365148103 cites W1757407923 @default.
• W4365148103 cites W1971837077 @default.
• W4365148103 cites W1973076899 @default.
• W4365148103 cites W1981671364 @default.
• W4365148103 cites W1982956862 @default.
• W4365148103 cites W1983849994 @default.
• W4365148103 cites W1998417832 @default.
• W4365148103 cites W2003319148 @default.
• W4365148103 cites W2030624854 @default.
• W4365148103 cites W2037618846 @default.
• W4365148103 cites W2045270025 @default.
• W4365148103 cites W2059485540 @default.
• W4365148103 cites W2064106995 @default.
• W4365148103 cites W2095371274 @default.
• W4365148103 cites W2127738463 @default.
• W4365148103 cites W2150305796 @default.
• W4365148103 cites W2162171505 @default.
• W4365148103 cites W2560499218 @default.
• W4365148103 cites W2765356289 @default.
• W4365148103 cites W2791703762 @default.
• W4365148103 cites W2809889937 @default.
• W4365148103 cites W2913004161 @default.
• W4365148103 cites W2968989098 @default.
• W4365148103 cites W3087754844 @default.
• W4365148103 cites W3096906134 @default.
• W4365148103 cites W3137696361 @default.
• W4365148103 cites W3213277274 @default.
• W4365148103 cites W4200388794 @default.
• W4365148103 cites W4220955338 @default.
• W4365148103 doi "https://doi.org/10.3390/cancers15082245" @default.
• W4365148103 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37190173" @default.
• W4365148103 hasPublicationYear "2023" @default.
• W4365148103 type Work @default.
• W4365148103 citedByCount "0" @default.
• W4365148103 crossrefType "journal-article" @default.
• W4365148103 hasAuthorship W4365148103A5017605873 @default.
• W4365148103 hasAuthorship W4365148103A5032410140 @default.
• W4365148103 hasAuthorship W4365148103A5036152679 @default.
• W4365148103 hasAuthorship W4365148103A5037048002 @default.
• W4365148103 hasAuthorship W4365148103A5062453235 @default.
• W4365148103 hasAuthorship W4365148103A5065381120 @default.
• W4365148103 hasAuthorship W4365148103A5069522018 @default.
• W4365148103 hasAuthorship W4365148103A5070418195 @default.
• W4365148103 hasAuthorship W4365148103A5081103160 @default.
• W4365148103 hasAuthorship W4365148103A5082155887 @default.
• W4365148103 hasAuthorship W4365148103A5088831248 @default.
• W4365148103 hasBestOaLocation W43651481031 @default.
• W4365148103 hasConcept C126322002 @default.
• W4365148103 hasConcept C126894567 @default.
• W4365148103 hasConcept C197934379 @default.
• W4365148103 hasConcept C203092338 @default.
• W4365148103 hasConcept C2777793932 @default.
• W4365148103 hasConcept C2778019345 @default.
• W4365148103 hasConcept C2778448856 @default.
• W4365148103 hasConcept C2779984678 @default.
• W4365148103 hasConcept C29730261 @default.
• W4365148103 hasConcept C2989005 @default.
• W4365148103 hasConcept C31760486 @default.
• W4365148103 hasConcept C535046627 @default.
• W4365148103 hasConcept C71924100 @default.
• W4365148103 hasConcept C90924648 @default.
• W4365148103 hasConceptScore W4365148103C126322002 @default.
• W4365148103 hasConceptScore W4365148103C126894567 @default.
• W4365148103 hasConceptScore W4365148103C197934379 @default.
• W4365148103 hasConceptScore W4365148103C203092338 @default.
• W4365148103 hasConceptScore W4365148103C2777793932 @default.
• W4365148103 hasConceptScore W4365148103C2778019345 @default.
• W4365148103 hasConceptScore W4365148103C2778448856 @default.
• W4365148103 hasConceptScore W4365148103C2779984678 @default.
• W4365148103 hasConceptScore W4365148103C29730261 @default.
• W4365148103 hasConceptScore W4365148103C2989005 @default.
• W4365148103 hasConceptScore W4365148103C31760486 @default.
• W4365148103 hasConceptScore W4365148103C535046627 @default.
• W4365148103 hasConceptScore W4365148103C71924100 @default.
• W4365148103 hasConceptScore W4365148103C90924648 @default.
• W4365148103 hasIssue "8" @default.
• W4365148103 hasLocation W43651481031 @default.
• W4365148103 hasLocation W43651481032 @default.
• W4365148103 hasLocation W43651481033 @default.
• W4365148103 hasOpenAccess W4365148103 @default.
• W4365148103 hasPrimaryLocation W43651481031 @default.
• W4365148103 hasRelatedWork W2037572837 @default.

• next